IS7413A - Nýjar 1,2,3,-setnar indólísín afleiður, hindrar af FGFS, aðferð við framleiðslu á þeim og lyfjafræðilegar samsetningar sem innihalda þau - Google Patents

Nýjar 1,2,3,-setnar indólísín afleiður, hindrar af FGFS, aðferð við framleiðslu á þeim og lyfjafræðilegar samsetningar sem innihalda þau

Info

Publication number
IS7413A
IS7413A IS7413A IS7413A IS7413A IS 7413 A IS7413 A IS 7413A IS 7413 A IS7413 A IS 7413A IS 7413 A IS7413 A IS 7413A IS 7413 A IS7413 A IS 7413A
Authority
IS
Iceland
Prior art keywords
fgfs
inhibitors
substituted
manufacture
new
Prior art date
Application number
IS7413A
Other languages
English (en)
Other versions
IS2475B (is
Inventor
Badorc Alain
Bono Françoise
Bordes Marie-Françoise
Guillo Nathalie
Herbert Jean-Marc
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of IS7413A publication Critical patent/IS7413A/is
Publication of IS2475B publication Critical patent/IS2475B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IS7413A 2002-04-04 2004-08-19 Nýjar 1,2,3,-setnar indólísín afleiður, hindrar af FGFS, aðferð við framleiðslu á þeim og lyfjafræðilegar samsetningar sem innihalda þau IS2475B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204220A FR2838123B1 (fr) 2002-04-04 2002-04-04 Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
PCT/FR2003/001030 WO2003084956A1 (fr) 2002-04-04 2003-04-02 NOUVEAUX DERIVES D'INDOLIZINE 1,2,3 SUBSTITUEE, INHIBITEURS DES FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

Publications (2)

Publication Number Publication Date
IS7413A true IS7413A (is) 2004-08-19
IS2475B IS2475B (is) 2008-12-15

Family

ID=28052118

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7413A IS2475B (is) 2002-04-04 2004-08-19 Nýjar 1,2,3,-setnar indólísín afleiður, hindrar af FGFS, aðferð við framleiðslu á þeim og lyfjafræðilegar samsetningar sem innihalda þau

Country Status (34)

Country Link
US (2) US7442708B2 (is)
EP (1) EP1495023B1 (is)
JP (1) JP4741799B2 (is)
KR (1) KR101022138B1 (is)
CN (1) CN100413863C (is)
AR (1) AR040404A1 (is)
AT (1) ATE304013T1 (is)
AU (1) AU2003240984B2 (is)
BR (1) BR0309026A (is)
CA (1) CA2476056C (is)
CO (1) CO5631442A2 (is)
DE (1) DE60301570T2 (is)
DK (1) DK1495023T3 (is)
EA (1) EA007902B1 (is)
EC (1) ECSP045338A (is)
ES (1) ES2247540T3 (is)
FR (1) FR2838123B1 (is)
HK (1) HK1074631A1 (is)
HR (1) HRP20040912B1 (is)
IL (2) IL163755A0 (is)
IS (1) IS2475B (is)
MA (1) MA27297A1 (is)
ME (2) MEP22508A (is)
MX (1) MXPA04009639A (is)
NO (1) NO329025B1 (is)
NZ (1) NZ534786A (is)
PL (1) PL215265B1 (is)
RS (1) RS51399B (is)
SI (1) SI1495023T1 (is)
TN (1) TNSN04188A1 (is)
TW (1) TWI335222B (is)
UA (1) UA78016C2 (is)
WO (1) WO2003084956A1 (is)
ZA (1) ZA200406613B (is)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.
CA2544786A1 (en) * 2003-11-04 2005-05-12 Dnavec Research Inc. Method for producing gene transferred dendritic cells
FR2865934B1 (fr) * 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
CN101006172B (zh) * 2004-06-24 2012-09-05 株式会社载体研究所 包含导入了rna病毒的树突状细胞的抗癌剂
US20090042820A1 (en) * 2004-11-22 2009-02-12 Threshold Pharmaceuticals, Inc. Tubulin Binding Anti Cancer Agents And Prodrugs Thereof
FR2883286B1 (fr) * 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
FR2896247B1 (fr) * 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP1891955A1 (en) * 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
WO2010027762A1 (en) * 2008-09-04 2010-03-11 Boehringer Ingelheim International Gmbh Indolizine inhibitors of leukotriene production
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
EP2270043A1 (en) * 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
CN101648953B (zh) * 2009-09-24 2012-09-05 绍兴文理学院 一种咪唑并[1，2-b]吡咯并[1，2-f]哒嗪衍生物及其制备方法和用途
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2967412B1 (fr) * 2010-11-17 2012-12-14 Sanofi Aventis Nouveaux derives d'indolizine, leur preparation et leur application en therapeutique
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
US10065955B2 (en) * 2014-12-10 2018-09-04 Ono Pharmaceutical Co., Ltd. Dihydroindolizinone derivative
EP3318563A1 (en) * 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
CN108864083B (zh) * 2018-06-07 2021-05-25 广东药科大学 一类具有抗癌活性的氨基取代吲嗪类化合物及其衍生物
CN110251513A (zh) * 2019-07-03 2019-09-20 南京大学 一种含吡唑的中氮茚化合物在制备抗肿瘤药物中的应用
US11976066B1 (en) 2023-10-23 2024-05-07 King Faisal University Substituted 7-amino-3-(substituted benzoyl)indolizine-1-carboxylates as anti-tubercular agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
US4378362A (en) 1979-12-06 1983-03-29 S.A. Labaz N.V. Indolizine derivatives and process for preparing the same
FR2528845A1 (fr) * 1982-06-17 1983-12-23 Sanofi Sa Nouveaux derives d'indolizine, leur procede de preparation ainsi que les compositions therapeutiques les contenant
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
GB9318790D0 (en) * 1993-09-10 1993-10-27 Fujisawa Pharmaceutical Co Heterocyclic derivatives
CA2373990C (en) * 1999-05-21 2007-05-08 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
EP1399442B1 (en) 2001-06-06 2006-08-09 Vertex Pharmaceuticals Incorporated Cak inhibitors and uses thereof
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
AU2003240984A1 (en) 2003-10-20
US7442708B2 (en) 2008-10-28
RS51399B (en) 2011-02-28
JP2005532286A (ja) 2005-10-27
ES2247540T3 (es) 2006-03-01
NO20044156L (no) 2005-01-03
ME00118B (me) 2010-10-10
DK1495023T3 (da) 2005-12-27
SI1495023T1 (sl) 2005-12-31
US7803811B2 (en) 2010-09-28
NZ534786A (en) 2006-06-30
PL215265B1 (pl) 2013-11-29
CA2476056C (fr) 2012-03-06
CA2476056A1 (fr) 2003-10-16
IL163755A0 (en) 2005-12-18
WO2003084956A1 (fr) 2003-10-16
ATE304013T1 (de) 2005-09-15
US20090023770A1 (en) 2009-01-22
FR2838123B1 (fr) 2005-06-10
EP1495023A1 (fr) 2005-01-12
TW200306181A (en) 2003-11-16
EA200400994A1 (ru) 2005-06-30
MEP22508A (en) 2010-06-10
MXPA04009639A (es) 2005-07-13
HRP20040912B1 (hr) 2012-10-31
KR20040099388A (ko) 2004-11-26
HK1074631A1 (en) 2005-11-18
TWI335222B (en) 2011-01-01
EP1495023B1 (fr) 2005-09-07
ECSP045338A (es) 2005-03-10
TNSN04188A1 (fr) 2007-03-12
CN100413863C (zh) 2008-08-27
CO5631442A2 (es) 2006-04-28
HRP20040912A2 (en) 2004-12-31
US20050203126A1 (en) 2005-09-15
RS86404A (en) 2006-12-15
DE60301570D1 (de) 2005-10-13
PL372812A1 (en) 2005-08-08
CN1649867A (zh) 2005-08-03
DE60301570T2 (de) 2006-05-18
IL163755A (en) 2010-11-30
EA007902B1 (ru) 2007-02-27
AU2003240984B2 (en) 2008-07-31
FR2838123A1 (fr) 2003-10-10
JP4741799B2 (ja) 2011-08-10
UA78016C2 (uk) 2007-02-15
ZA200406613B (en) 2007-12-27
NO329025B1 (no) 2010-08-02
BR0309026A (pt) 2005-02-09
MA27297A1 (fr) 2005-05-02
AR040404A1 (es) 2005-04-06
IS2475B (is) 2008-12-15
KR101022138B1 (ko) 2011-03-17

Similar Documents

Publication Publication Date Title
IS2475B (is) Nýjar 1,2,3,-setnar indólísín afleiður, hindrar af FGFS, aðferð við framleiðslu á þeim og lyfjafræðilegar samsetningar sem innihalda þau
IS7735A (is) Bensódíasepín afleiður og lyfjasamsetningar sem innihalda þær.
IS7226A (is) Fjölbrigða form af rimonabant, framleiðsluaðferð og lyfjasamsetningar sem innihalda það
DK1150961T3 (da) Pyrazolcarboxylsyrederivater, fremstilling af disse og farmaceutiske præparater indeholdende disse
HK1167332A1 (en) Pharmaceutical composition, use thereof and method for making the same
IS7261A (is) N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær
IS5747A (is) Oxazólidínón afleiður, aðferð fyrir framleiðslu þeirra og lyfjasamsetninga sem innihalda þær
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
IL163117A (en) Indazole derivatives and pharmaceutical compositions containing the same
IS2040B (is) Pýrasólínafleiður, framleiðsla þeirra og notkun sem lyfja
IL166620A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
PL380851A1 (pl) Nowe pochodne pirydynowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne
IS8383A (is) Nýjar afleiður af 4a,5,9,10,11,12-hexahýdróbensófúró[3a,3,2][2]-bensasepín, aðferð við framleiðslu þeirra og notkun þeirra við framleiðslu á lyfjum
HUP0400193A3 (en) Imidazolindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
PL347105A1 (en) Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof
HK1090356A1 (en) 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them
IS7551A (is) Stilltar lyfjafræðilegar samsetningar sem byggðareru á pólýoxýetýlaðri laxerolíu og aðferð við að framleiða þær
HUP0400549A3 (en) Novel imidazole derivatives, production method thereof and pharmaceutical compositions containing them
NO20023662L (no) Nye heterocykliske derivater, fremgangsmåte ved fremstilling og farmasöytiske sammensetninger inneholdende det samme
PL366381A1 (en) Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives
NO20031396D0 (no) Derivater av tryptamin og analoge sammensetninger, og farmasöytiske formuleringer som inneholder disse
PL374761A1 (en) N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them
IS2338B (is) Nýjar morfólínafleiður, aðferð til framleiðslu þeirra og lyfjablöndur sem innihalda þessar afleiður
DK1263719T3 (da) N-deacetylthiocolchin-derivater og farmaceutiske sammensætninger indeholdende disse.